Management of Acne Vulgaris by Lewis, Jelena
Chapman University 
Chapman University Digital Commons 
Pharmacy Faculty Articles and Research School of Pharmacy 
9-2-2017 
Management of Acne Vulgaris 
Jelena Lewis 
Chapman University, jelewis@chapman.edu 
Follow this and additional works at: https://digitalcommons.chapman.edu/pharmacy_articles 
 Part of the Other Pharmacy and Pharmaceutical Sciences Commons 
Recommended Citation 
Lewis J. Management of acne vulgaris. Pharmacy Times. https://www.pharmacytimes.com/publications/
supplementals/2017/dermatologysupplementjuly2017/management-of-acne-vulgaris. Published 
September 2, 2017. 
This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital 
Commons. It has been accepted for inclusion in Pharmacy Faculty Articles and Research by an authorized 
administrator of Chapman University Digital Commons. For more information, please contact 
laughtin@chapman.edu. 
Management of Acne Vulgaris 
Comments 
This article was originally published on Pharmacy Times in September 2017. 
Copyright 
Pharmacy Times 
This article is available at Chapman University Digital Commons: https://digitalcommons.chapman.edu/
pharmacy_articles/776 
Management of Acne Vulgaris 
2017-09-02 18:33:00 
Jelena Lewis, PharmD 
 
About 50 million people in the Unites States have acne vulgaris (AV) (figure1), a common 
inflammatory skin disease that predominantly affects adolescents and young adults. Although it 
can occur in any age group, AV affects about 85% of teenagers.1,2 The prevalence of acne in 
adult women is about 12%.3 Although acne is not associated with mortality, it does pose a 
physical and psychological burden to the patient, which may result in depression, negative body 
image, stress, and anxiety. The direct cost of the disease is estimated to exceed $3 billion per 
year.2 Therefore, it is imperative that clinicians are familiar with the management of AV, which 
consists of topical therapies, systemic antibiotics, hormonal agents, and isotretinoin.4 A treatment 
algorithm for the management of AV in adolescents and young adults is outlined in the table4. 
 
TOPICAL THERAPIES  
Topical therapies used for acne treatment may be OTC or prescription products. Commonly used 
topical acne products include benzoyl peroxide (BP), either as monotherapy or in combination; 
antibiotics and retinoids, either as monotherapy or in combination; salicylic acid; azelaic acid; 
and sulfone agents.4 
 
BP may be used as monotherapy or in combination with topical erythromycin or clindamycin for 
treatment of mild acne4; BP may also be used in conjunction with a topical retinoid or systemic 
antibiotic therapy for treatment of moderate to severe acne.4 BP is an antibacterial agent with low 
likelihood of resistance. Formulations of topical BP include washes, foams, creams, and gels, 
used in both leave-on or wash-off agents.4 Topical BP products are available in the strengths of 
2.5% to 10% and results may be seen in as little as 5 days.4,5 Adverse effects (AEs) include 
concentration-dependent irritation and contact allergy which are uncommon. Longer skin contact 
times and certain formulations may provide better results. Lower BP concentrations and wash-
off agents may be preferred in patients with sensitive skin. BP can safely be used in the 
management of preadolescent acne in children. Patients should be made aware that BP may stain 
or bleach fabrics.4 
 
Most patients with acne will need combination therapy. The addition of BP to antibiotic therapy 
enhances results, and reduces development of resistant bacterial strains. Monotherapy with 
topical antibiotics is not recommended due to increased risk for antibiotic resistance. 
Clindamycin 1% and erythromycin 2% are topical antibiotics available for the treatment of acne 
and are available as fixed-combination agents with BP. Topical clindamycin is preferred over 
topical erythromycin as some bacteria are resistant to erythromycin. Topical antibiotics are well 
tolerated and treatment is associated with a low risk of AEs (eg, diarrhea).4 
 
Retinoids are an important first-line topical therapy for comedonal acne; however, retinoids 
increase the efficacy and acne-clearing benefits when used with other topical or oral agents in 
combination regimens. Retinoids function to resolve the primary acne lesion, as well as inhibit 
the formation of new comedones, and they have anti-inflammatory properties. Taken together 
with other topical or oral agents, retinoid treatment allows for extended acne clearance in the 
maintenance phase after cessation of oral therapy.4 Tretinoin, adapalene, and tazarotene are 
topical retinoids and vitamin A derivatives used in the treatment of acne. Of the retinoid 
combination products available for the topical treatment of acne, 2 topical gel products are 
formulated with a fixed combination of retinoid and antibiotic agents (clindamycin phosphate 
1.2%/tretinoin 0.025%) and 2 topical gel products are formulated with a fixed combination of 
retinoid and BP (adapalene 0.1%/BP 2.5%).4,6-8 Most retinoids are approved by the FDA for 
patients ≥12 years of age with the exception of tretinoin 0.05% micronized tretinoin gel, which is 
approved for patients ≥10 years of age, and adapalene 0.1%/BP 2.5%, which is approved for 
patients ≥9 years of age.4 Patients treated with retinoids may experience AEs including dryness, 
peeling, irritation, and erythema.4,9 Patients using both tretinoin and BP should be counseled 
about applying these 2 products at different times, as tretinoin may be deactivated by BP. 
Tretinoin microsphere formulation, adapalene, and tazarotene do not have these restrictions. 
Patients using retinoids should also be counseled to wear sunscreen daily, as these agents have an 
increased risk of photosensitivity. Prior to initiating treatment with tazarotene, a negative 
pregnancy test should be ensured and patients should be counseled regarding pregnancy risks, as 
this medication is classified as pregnancy category X. Tretinoin and adapalene are classified as 
pregnancy category C.4 There are limited data as to which retinoid is most effective. Therefore, 
which product to use may simply be patient or physician preference. 
 
Azelaic acid 20% is a mildly effective agent and has benefits in patients with sensitive skin. It is 
useful as an adjunctive agent and can be recommended in the treatment of post-inflammatory 
dyspigmentation.4 
 
Dapsone 5% gel is a sulfone agent used twice daily and it has modest to moderate efficacy. 
Dapsone is believed to provide benefit as an anti-inflammatory agent; however, treatment has 
demonstrated increased benefits in women compared with effects in men and adolescents.4,10,11 
When used with BP, dapsone may cause orange-brown coloration of the skin, which may be 
washed off.4 Patients should be counseled regarding this occurrence. Dapsone is indicated for 
patients ≥12 years old and it does not necessitate glucose-6-phosphate dehydrogenase testing 
prior to the start of the medication.4 
 
The topical therapies salicylic acid, sulfur, resorcinol, aluminum chloride, topical zinc alone, 
sodium sulfacetamide, and topical niacinamide all have limited data regarding efficacy for the 
treatment of AV.4 
 
SYSTEMIC ANTIBIOTICS  
Systemic antibiotics are used for moderate to severe inflammatory acne and should be used in 
combination with a topical retinoid or BP.4,12-14 The tetracycline class of antibiotics is considered 
a first-line treatment for moderate to severe acne. Both doxycycline and minocycline have 
demonstrated increased efficacy compared with tetracycline in the treatment of moderate to 
severe acne; however, there are no differences in efficacy between the 2 systemic antibiotic 
treatments. Macrolide antibiotics such as erythromycin or azithromycin can also be used in the 
treatment of acne, but these agents are usually reserved for patients who cannot take tetracyclines 
(ie, children <8 years of age and pregnant women). Data are limited for the use of systemic 
antibiotics, other than tetracyclines and macrolides, for the treatment of acne.4 
 
Patients may ask about the AEs of taking systemic antibiotics for acne. Severe AEs of systemic 
antibiotics in the treatment of acne are rare.4 Photosensitivity is a major AE of tetracyclines. 
Gastrointestinal (GI) disturbances have also been reported. Fewer case reports of AEs have been 
reported for doxycycline than minocycline.4,15 AEs associated with minocycline include 
dizziness and tinnitus, as well as pigment deposition of the teeth, mucous membranes, and skin.4 
Minocycline may also cause more serious AEs such as autoimmune disorders, drug-induced 
lupus, and other hypersensitivity reactions, while the predominant serious AE for doxycycline is 
esophageal erosion.15 Macrolides are also associated with GI disturbances, and this is higher with 
erythromycin than azithromycin. This class of antibiotics may cause cardiac conduction 
abnormalities, and azithromycin has also been associated with cutaneous hypersensitivity 
reaction. Although some patients may need prolonged therapy with systemic antibiotics for the 
treatment of AV, limiting use of these agents to 3 months is preferred in order to avoid antibiotic 
resistance. Systemic antibiotics should be administered concomitantly with either a topical 
therapy with BP or a retinoid; this topical treatment can continue for maintenance after systemic 
antibiotic therapy has been completed.4 
 
HORMONAL AGENTS  
Ethinyl estradiol/norgestimate, ethinyl estradiol/norethindrone acetate/ferrous fumarate, ethinyl 
estradiol/drospirenone, and ethinyl estradiol/drospirenone/levomefolate are the 4 combination 
oral contraceptive pills (COCs) approved by the FDA for the treatment of AV in women who 
also desire contraception. All 4 of these medications are equally efficacious when used for the 
treatment of AV and may be used alone or in combination with other treatments. Venous 
thromboembolic events, myocardial infarction (MI), ischemic and hemorrhagic stroke, breast 
cancer, and cervical cancer are associated with COC use. MI risk is strongly associated with 
cigarette smoking, diabetes mellitus, and hypertension. Cigarette smoking and hypertension 
contribute to increased risk of stroke, as do higher doses of ethinyl estradiol and being older than 
35 years of age. Furthermore, due to concern regarding COC use in younger adolescent 
populations given the effects of low estrogen on bone mass, the use of COC for acne should be 
avoided unless the patient is at least 14 years of age and started menses more than 2 years prior 
to treatment. COCs used for the treatment of AV are approved for female patients desiring 
contraception who are either ≥14 or ≥15 years of age. Patients should also be counseled that the 
benefits of COC therapy will not be seen immediately and that the visible effects may take 
several months.4  
 
Spironolactone is not FDA-approved for the treatment of AV. However, the guidelines produced 
by the American Academy of Dermatology (AAD) for the care and management of acne vulgaris 
support the use of spironolactone in the management of acne in select women. Spironolactone 
has a black box warning that it has been shown to be a tumorigen in chronic toxicity studies in 
rats; because of this, off-label use of spironolactone should be avoided. One report documented 
carcinogenicity associated with spironolactone treatment in 5 hospitalized patients with breast 
cancer; however, additional retrospective studies have shown no association between 
spironolactone use and breast cancer. Spironolactone may be used safely with drospirenone-
containing COCs. Serum potassium monitoring is recommended for high-risk patients who are 
older or taking angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, 
nonsteroidal anti-inflammatory drugs, or digoxin.4 Patients taking this medication should be 




Oral isotretinoin has been used in the United States for more than 30 years and is approved by 
the FDA for the treatment of severely recalcitrant AV. AAD guidelines of care for the 
management of AV also support the use of oral isotretinoin for use in moderate AV that is 
treatment-resistant or quick-relapsing, or in patients who have significant scarring or 
psychosocial issues due to AV. Patients taking isotretinoin should be counseled to take this 
medication with food. Isotretinoin treatment is associated with AEs including inflammatory 
bowel disease (IBD), cardiovascular risk factors, depression or other mood changes, bone 
demineralization, concerns regarding scarring with procedures such as dermabrasion or laser 
resurfacing, and Staphylococcus aureus colonization which may increase the risk for skin 
infections.4 Although the risk for these AEs is low, patients should be educated regarding the 
potential risks for these events. The AAD states that the evidence is insufficient to prove either 
an association or causal relationship between isotretinoin use and IBD. The AAD also states that 
an evidence-based causal relationship between isotretinoin use and depression/anxiety symptoms 
has not been established.17 Liver function tests and lipid panel should be routinely monitored 
while on isotretinoin therapy. Complete blood cell counts are not necessary.4 Isotretinoin is a 
teratogen and patients must be counseled regarding this. All patients (not just women), 
prescribers, pharmacies, and manufacturers must register with the iPLEDGE program, which 
was designed to prevent fetal exposure to isotretinoin. Despite this, fetal exposure has not 
significantly decreased since the implementation of iPLEDGE, and about 150 isotretinoin-
exposed pregnancies still occur annually in the United States.18,19 Therefore, pharmacists must be 
diligent about counseling patients regarding either abstinence or the importance of adherence to 
2 contraceptive methods as per iPLEDGE requirements.19 
 
OTHER THERAPIES  
Other therapies for the treatment of acne include glycolic acid peels, salicylic acid peels, and 
pulsed dye laser treatments; however, there is little evidence to support the recommendation of 
these procedures. Safety and efficacy have not been established for complementary and 
alternative therapies for the treatment of AV. Currently, there is no “acne diet”; however, some 
data show that a diet with a high glycemic index and intake of dairy products may predispose 
patients to acne.4 
 
CONCLUSION  
Many available agents are used for the management of AV. These agents may cause AEs or 
require routine lab monitoring in certain patients. Pharmacists should ensure that patients taking 
these medications are counseled regarding potential AEs, and they should recommend routine 
laboratory monitoring to patients and physicians as deemed appropriate. 
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